SCHEMBL5525210

SCHEMBL5525210

COc1ccc(C(=O)Nc2ccn([C@@H]3O[C@@H]4CO[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)O[C@H]4[C@H]3O[Si](C)(C)C)c(=O)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ RIN1 Q13671 1/20 0.36
▸ P2RY6 Q15077 3/20 0.35
▸ P2RY14 Q15391 2/20 0.35
▸ NT5E P21589 1/20 0.35
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CCNA1 P78396 1/20 0.34
▸ NPC1 O15118 3/20 0.33
▸ TP53 P04637 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ P2RY2 P41231 1/20 0.32
▸ P2RY4 P51582 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531861 0.92 P2RY6 (0.40) POLBABL1RIN1P2RY6P2RY14
SCHEMBL5526499 0.88 ABL1 (0.34) POLBABL1RIN1P2RY6P2RY14
SCHEMBL6932273 0.87 POLB (0.44) POLBABL1RIN1P2RY6P2RY14
SCHEMBL12404747 0.85 POLB (0.49) POLBABL1RIN1P2RY6P2RY14
SCHEMBL6365679 0.84 POLB (0.45) POLBABL1RIN1P2RY6P2RY14
SCHEMBL7736293 0.83 POLB (0.43) POLBABL1RIN1P2RY6P2RY14
SCHEMBL6365808 0.82 P2RY6 (0.47) POLBABL1RIN1P2RY6P2RY14
SCHEMBL13672352 0.82 P2RY6 (0.47) POLBABL1RIN1P2RY6P2RY14
SCHEMBL13151571 0.82 P2RY6 (0.47) POLBABL1RIN1P2RY6P2RY14
SCHEMBL30274756 0.80 ACHE (0.33) POLBABL1RIN1P2RY6P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070172925-A1 Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound NIPPON SHINYAKU CO., LTD. (JP) 2007-07-26 — — US disclosed
EP-1710249-A1 RIBONUCLEIC ACID COMPOUND AND METHOD OF LIQUID-PHASE SYNTHESIS OF OLIGONUCLEIC ACID COMPOUND Nippon Shinyaku Co., Ltd. (JP) 2006-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070172925-A1 Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound RNASEH1, NSUN2, POLR2H POLB 40/4885ABL1 3391/4885RIN1 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback